Literature DB >> 35290879

NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives.

Victoria Casado-Medrano1, Alison O'Neill1, Stephen Halada1, Theodore W Laetsch2, Andrew J Bauer1, Aime T Franco3.   

Abstract

Pediatric and adult papillary thyroid cancer (PTC) share many similar oncogenic drivers, but differ in the pathological features and outcomes of the disease. The most frequent genetic alterations in adult PTCs are mutually exclusive point mutations in BRAF or the RAS family. In pediatric PTC, fusion oncogenes involving chromosomal translocations in tyrosine kinase (TK) receptors, most commonly RET and NTRK, are the most common genetic alterations observed. This review of the literature describes the current state of translational research in pediatric NTRK-driven thyroid cancer and highlights opportunities to improve our understanding and current models of pediatric PTC.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Keywords:  Adult thyroid cancer; Mouse models; NTRK fusion; Oncogene; Pediatric

Mesh：

Substances：

Year:  2022        PMID： 35290879      PMCID： PMC9133211          DOI： 10.1016/j.cancergen.2022.02.009

Source DB:  PubMed          Journal:  Cancer Genet


  56 in total

1.  Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

Authors:  Alexander Drilon; Sai-Hong Ignatius Ou; Byoung Chul Cho; Dong-Wan Kim; Jeeyun Lee; Jessica J Lin; Viola W Zhu; Myung-Ju Ahn; D Ross Camidge; Judy Nguyen; Dayong Zhai; Wei Deng; Zhongdong Huang; Evan Rogers; Juliet Liu; Jeff Whitten; John K Lim; Shanna Stopatschinskaja; David M Hyman; Robert C Doebele; J Jean Cui; Alice T Shaw
Journal:  Cancer Discov       Date:  2018-08-09       Impact factor: 39.397

2.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

3.  Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.

Authors:  Lindsey Mortensen; Zehra Ordulu; Ibiayi Dagogo-Jack; Veerle Bossuyt; Loren Winters; Alphonse Taghian; Barbara L Smith; Leif W Ellisen; Lesli A Kiedrowski; Jochen K Lennerz; Aditya Bardia; Laura M Spring
Journal:  Oncologist       Date:  2021-06-27

4.  Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Authors:  James Nagarajah; Mina Le; Jeffrey A Knauf; Giuseppe Ferrandino; Cristina Montero-Conde; Nagavarakishore Pillarsetty; Alexander Bolaender; Christopher Irwin; Gnana Prakasam Krishnamoorthy; Mahesh Saqcena; Steven M Larson; Alan L Ho; Venkatraman Seshan; Nobuya Ishii; Nancy Carrasco; Neal Rosen; Wolfgang A Weber; James A Fagin
Journal:  J Clin Invest       Date:  2016-09-26       Impact factor: 14.808

5.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.

Authors:  Ralph Meuwissen; Sabine C Linn; R Ilona Linnoila; John Zevenhoven; Wolter J Mooi; Anton Berns
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

6.  Dramatic response of STRN-NTRK-fused malignant glioneuronal tumor to larotrectinib in adult.

Authors:  Julie Boyer; Cristina Birzu; Franck Bielle; Clara Goulas; Julien Savatovsky; Carine Karachi; Ahmed Idbaih
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 13.029

7.  Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.

Authors:  Bruce W Konicek; Andrew R Capen; Kelly M Credille; Philip J Ebert; Beverly L Falcon; Gary L Heady; Bharvin K R Patel; Victoria L Peek; Jennifer R Stephens; Julie A Stewart; Stephanie L Stout; David E Timm; Suzane L Um; Melinda D Willard; Isabella H Wulur; Yi Zeng; Yong Wang; Richard A Walgren; Sau-Chi Betty Yan
Journal:  Oncotarget       Date:  2018-02-13

Review 8.  Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib.

Authors:  Neda Stjepanovic; Jaume Capdevila
Journal:  Biologics       Date:  2014-04-10

Review 9.  TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs.

Authors:  Sun-Young Han
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-29

10.  Diagnostic challenges and successful organ-preserving therapy in a case of secretory carcinoma of minor salivary glands.

Authors:  Ruben Bill; Daniel G Deschler; Mikael J Pittet; Sara I Pai; Peter M Sadow; Jong Chul Park
Journal:  Cancer Rep (Hoboken)       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.